Skip to main content

RenovoRx, Inc. (RNXT) Stock Forecast

Data as of Sep 19, 2026

Healthcare · Current price $1.71 (-1.45%)

Consensus Target
Upside
Analysts
4
Rating
Buy(2.00)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

RNXT vs Sector & Market

MetricRNXTHealthcare AvgLarge Cap Avg
Analyst Rating2.002.262.42
Analyst Count4818
Target Upside+22217.1%+21.5%
P/E Ratio-2.663.7638.34

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$3M$4M$4M2
2027-12-31$9M$11M$13M2
2028-12-31$33M$35M$36M3
2029-12-31$128M$156M$191M2
2030-12-31$291M$354M$433M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.26$-0.23$-0.201
2027-12-31$-0.19$-0.15$-0.122
2028-12-31$-0.03$-0.01$0.033
2029-12-31$0.64$0.84$1.081
2030-12-31$1.81$2.35$3.041

Frequently Asked Questions

What is the analyst consensus for RNXT?

The consensus among 4 analysts covering RenovoRx, Inc. (RNXT) is Buy with an average price target of N/A.

How many analysts cover RNXT?

4 analysts have issued ratings for RenovoRx, Inc. in the past 12 months.

Is RNXT a buy or sell right now?

Based on 4 analyst ratings, RNXT has a consensus rating of Buy (2.00/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for RNXT?

Analysts estimate RNXT will report EPS of $-0.23 for the period ending 2026-12-31, with revenue estimated at $4M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.